Patents by Inventor Roland Mertelsmann
Roland Mertelsmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220221336Abstract: For the improved autonomous control of a process (2) using an apparatus (1) via setting of at least one action parameter (3) controlling the process (2), it is provided that via a measuring instrument (17), preferably a spectrometer (18) integrated into the apparatus (1), a process response (4), which the process (2) transfers in reaction to an adjustment of the at least one action parameter (3) to its immediate environment, is measured and evaluated in a computer-implemented manner, preferably using an artificial intelligence, and that based on this evaluation, the at least one action parameter (3) is automatically readjusted. This approach is applicable to biological, chemical and physical processes.Type: ApplicationFiled: January 12, 2022Publication date: July 14, 2022Applicant: BioThera Institut GmbHInventors: Roland MERTELSMANN, Joschka BÖDECKER, Dennis RAITH, Jonas BERMEITINGER
-
Publication number: 20210269762Abstract: A method for setting up an apparatus (1) for biological processes (3), in which process parameters are specified for a plurality of biological processes (3) with computer assistance, that for each biological process (3) a process state is automatically captured, that the particular process state is evaluated using a specified objective with computer assistance, and that from the evaluations the apparatus (1) is set up, with computer assistance, through specification of learned set-up parameters. In addition, an apparatus (1) for biological processes (3) is provided with which the proposed method can be carried out in a particularly advantageous manner.Type: ApplicationFiled: July 16, 2019Publication date: September 2, 2021Applicant: BioThera Institut GmbHInventors: Roland MERTELSMANN, Justus DUYSTER, Marie FOLLO, Sascha LANGE, Maximiliano S. PEREZ
-
Publication number: 20050063946Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5×108 U/mg protein.Type: ApplicationFiled: October 5, 2004Publication date: March 24, 2005Inventors: Karl Welte, Erich Platzer, Janice Gabrilove, Roland Mertelsmann, Malcolm Moore
-
Patent number: 6838549Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5×108 U/mg protein.Type: GrantFiled: April 4, 2002Date of Patent: January 4, 2005Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsmann, Malcolm A. S. Moore
-
Publication number: 20030078197Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5×108 U/mg protein.Type: ApplicationFiled: April 4, 2002Publication date: April 24, 2003Inventors: Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsmann, Malcolm A.S. Moore
-
Patent number: 6114166Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.Type: GrantFiled: December 22, 1997Date of Patent: September 5, 2000Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsmann, Malcolm A. S. Moore
-
Patent number: 6093393Abstract: The invention relates to a process for preparing clonogenic fibroblasts, with tissue being removed from the donor and the individual cells being isolated from the tissue, the resulting cell suspension being strained, the cells which are contained in the cell suspension being washed and the cells being converted into a tissue culture, with the exception of the isolation of individual cells by mechanical comminution, followed by an enzymic treatment with collagenase alone, and with at least one gene being inserted into the fibroblasts by means of the transfection, which gene encodes a biologically active protein, preferably a therapeutically active protein, for example a growth factor, a hormone, an enzyme, a coagulation factor or a coagulation inhibitor.Type: GrantFiled: August 22, 1996Date of Patent: July 25, 2000Inventors: Felicia Rosenthal, Albrecht Lindemann, Thomas Boehm, Roland Mertelsmann, Hendrik Veelken, Peter Kulmburg
-
Patent number: 5866115Abstract: Dendritic cells are of interest therapeutically as antigen-presenting cells. A process is disclosed in which peripheral blood cells are first isolated and the CD 34 antigen-expressing blood progenitor cells which they contain are then enriched. These enriched cells are expanded ex-vivo using a combination of haematopoietic growth factors and cytokines. Over a period of 10-20 days, they give rise, in particular to dendritic cells which, where appropriate, can be purified still further. These cells are functionally active with regard to the ability to present antigen.Type: GrantFiled: October 11, 1996Date of Patent: February 2, 1999Assignee: Klinikum Der Albert-Ludwigs-Universitat FreiburgInventors: Lothar Kanz, Wolfram Brugger, Reinhard Henschler, Gabriele Kohler, Hans-Eckart Schaefer, Albrecht Lindemann, Roland Mertelsmann, Andreas Mackensen, Paul Fisch, Birgit Herbst
-
Patent number: 5824330Abstract: This invention provides a composition comprising a therapeutically effective amount of purified human interleukin-2 and a pharmaceutically acceptable carrier.Type: GrantFiled: April 4, 1994Date of Patent: October 20, 1998Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Roland Mertelsmann, Karl Welte, Salvatore Venuta
-
Patent number: 5808008Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.Type: GrantFiled: March 12, 1997Date of Patent: September 15, 1998Assignee: Sloan-Kettering Institute of Cancer ResearchInventors: Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsmann, Malcolm A. S. Moore
-
Patent number: 5662895Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.Type: GrantFiled: June 7, 1995Date of Patent: September 2, 1997Assignee: Sloan-Kettering InstituteInventors: Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsmann, Malcolm A. S. Moore
-
Patent number: 5541103Abstract: Patients suffering from certain types of cancer are treated by high-dose chemotherapy. In order to allow a recovery a process for the ex vivo expansion of peripheral blood progenitor cells is described, wherein CD 34.sup.+ -cells are enriched and cultivated in a medium comprising IL-1, IL-3, IL-6, EPO and SCF. The ex vivo expanded peripheral blood progenitor cells can be administered to cancer patients after chemotherapy.Type: GrantFiled: June 6, 1995Date of Patent: July 30, 1996Assignee: Klinikum der Albert-Ludwigs-Universitat FreiburgInventors: Lothar Kanz, Wolfram Brugger, Roland Mertelsmann
-
Patent number: 5532341Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.Type: GrantFiled: July 26, 1994Date of Patent: July 2, 1996Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsmann, Malcolm A. S. Moore
-
Patent number: 4925919Abstract: Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH.sub.4).sub.2 SO.sub.4 -precipitation, ion-exchange chromatogrThis invention was made with support in part under Grants CA 08748, CA 22507, CA 25608, CA 20194, CA 21525, CA31525, P01-CA-20194, AI 18 321-01, CA 23766 and CA 33050 awarded by the National Cancer Institute, National Institute of Health, DHEW. The government has certain rights in this invention.Type: GrantFiled: June 10, 1988Date of Patent: May 15, 1990Inventors: Roland Mertelsmann, Karl Welte, Salvatore Venuta
-
Patent number: 4908434Abstract: Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal humaThis invention was made with support in part under Grants CA 08748, CA 22507, CA 25608, CA 20194, CA 21525, CA 31525, P01-CA-20194, AI 18 321-01, CA 23766 and CA 33050 awarded by the National Cancer Institute, National Institute of Health, DHEW. The government has certain rights in this invention.Type: GrantFiled: June 10, 1988Date of Patent: March 13, 1990Assignee: Sloan-Kettering institute for Cancer ResearchInventors: Roland Mertelsmann, Karl Welte, Salvatore Venuta
-
Patent number: 4908433Abstract: Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoThis invention was made with support in part under Grants CA 08748, CA 22507, CA 25608, CA 20194, CA 21525, CA31525, PO1-CA-20194, AI 18 321-01, CA 23766 and CA 33050 awarded by the National Cancer Institute, National Institute of Health, DHEW. The government has certain rights in this invention.Type: GrantFiled: June 10, 1988Date of Patent: March 13, 1990Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Roland Mertelsmann, Karl Welte, Salvatore Venuta
-
Patent number: 4778879Abstract: Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH.sub.4).sub.2 SO.sub.4 -precipitation, ion-exchange chromatography, gel filtration and hydrophobic chromatography. hp IL-2 is free of pyrogens, B cell inducing factor, B cell growth factor, interferon, CSF, and thymocyte differentiating factor. Nature IL 2 produced in the absence of Daudi cells has a molecular weight of about 26,000 daltons as measured by gel filtration and yields IL 2 having two molecular weights of about 16,000 and 17,000 daltons after denaturation as measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. IL 2 produced in the presence of Daudi cells shows a molecular weight of approximately 14,500 daltons as measured by both gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis.Type: GrantFiled: April 25, 1984Date of Patent: October 18, 1988Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Roland Mertelsmann, Karl Welte, Salvatore Venuta